1231930-13-4

Basic information

• Product Name: 3-bromo-2-methyl-6-nitroPyridine
• Synonyms: 3-bromo-2-methyl-6-nitroPyridine
• CAS NO: 1231930-13-4
• Molecular Formula: C6H5BrN2O2
• Molecular Weight: 217.0201
• Mol File: 1231930-13-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 3-bromo-2-methyl-6-nitroPyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-2-methyl-6-nitroPyridine(1231930-13-4)
• EPA Substance Registry System: 3-bromo-2-methyl-6-nitroPyridine(1231930-13-4)

Safety Data

• Hazardous Substances Data: 1231930-13-4(Hazardous Substances Data)

Usage

General Description

3-bromo-2-methyl-6-nitroPyridine is a chemical compound with the molecular formula C6H5BrN2O2. It is a pyridine derivative with a bromine atom at the 3rd position, a methyl group at the 2nd position, and a nitro group at the 6th position of the pyridine ring. 3-bromo-2-methyl-6-nitroPyridine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also utilized in the production of dyes, pigments, and other organic compounds. Additionally, it can be employed as a building block for the creation of various organic compounds in chemical research and development. Due to its potential applications, 3-bromo-2-methyl-6-nitroPyridine is considered an important chemical in the field of organic synthesis and chemical manufacturing.

Upstream product

• 42753-71-9 5-bromo-6-methyl-pyridin-2-ylamine 

Downstream Products

• 15128-84-4 2-methyl-6-nitropyridin-3-ol 

Relevant articles and documents

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

PROTEIN KINASE INHIBITORS

The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.